Cure8

Why This Matters

Compares widely used modelled GBD rates with population-based observations and finds they are not interchangeable for country-year estimates—important for research, surveillance, and policy that rely on these numbers.

Who Should Pay Attention

Researchers in IBD epidemiology, public-health analysts, clinicians and policymakers using GBD estimates

Study Snapshot

Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract

What To Know

The paper matched GBD 2023 rates to population-based incidence and prevalence observations from GIVES-21 and assessed agreement using Bland–Altman differences, Deming regression, and concordance correlation coefficients.

Median GBD-to-GIVES ratios were generally below 1 (GBD lower than observed) across incidence and prevalence for both UC and CD, and concordance varied by outcome and sensitivity analyses.

The authors emphasize that both data sources are imperfect: the analysis quantifies agreement but does not establish which source reflects the true underlying rates nor support applying a single correction factor to GBD estimates.

Keep In Mind

Structured content depth is abstract from a posted research paper on Research Square; it summarizes the authors' analyses but has not undergone peer review.

Source Details

Review the original publication for the complete reporting, methods, and context.

Read Original Source
Research paper Evidence type derived from source or registry metadata.
PublicationSpringer Science and Business Media LLC
AuthorsYingxia Luo, Guanhong Li, Jinghong Liu +2 more
Study typePosted Content
Indexed viaCrossref
Source typeResearch paper
PublishedAug 18, 2026, 12:00 AM
Content availableJournal abstract

This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.

Related Reading

Browse latest news →